Results for "Roivant Sciences"

Roivant Sciences presented at the Cantor conference, highlighting momentum in its pipeline following positive data from mosliciguat trials.

Analysis of how the $35,000 monthly price tag for Lisraya could impact the pharmaceutical company Roivant Sciences.

Investment firm H.C. Wainwright has maintained its buy recommendations for both IREN and Roivant Sciences, highlighting strong growth prospects driven by artificial intelligence revenue and clinical developments. The upgrades reflect analyst confidence in the companies' near-term performance.

Pfizer and BioNTech are facing global patent lawsuits from Arbutus and Roivant Sciences concerning the technology used in their COVID-19 vaccines.

TD Cowen, a financial services firm, has increased its price target for Roivant Sciences (ROIV) stock, indicating a positive outlook on the pharmaceutical company's future performance.

Roivant Sciences experienced gains in its stock value after positive mid-stage trial data was released for Immunovant’s primary asset.

Noted investor David Einhorn has reportedly trimmed his position in Roivant Sciences Ltd. (ROIV).

Shares of Roivant Sciences jumped 19% after the company reported positive clinical trial results for its drug candidate mosliciguat.

S&P 500 Futures Decline in Premarket Trading; Roivant Sciences, Bloom Energy Lead Barron's

Roivant Sciences will present top-line results from the Phase 2 PHocus Study of Mosliciguat for pulmonary hypertension associated with interstitial lung disease at the ERS Congress 2026.

The U.S. Food and Drug Administration has approved brepocitinib, marketed as LISRAYA, for the treatment of adult patients with dermatomyositis. Roivant Sciences announced the approval, making the medication commercially available across the United States.

An analysis is exploring whether Roivant Sciences has the potential to become a multibagger stock, delivering significant returns over the next five years.

Roivant Sciences (ROIV) saw its stock climb by 15% following the company's announcement of a swing to profitability.

Roivant Sciences Ltd (ROIV) saw a significant rally in the first quarter, with an article explaining the reasons behind its strong performance.

Joe Edelman has reportedly identified Roivant Sciences Ltd. (ROIV) as one of the best stocks to buy, drawing attention to the pharmaceutical company.

Jefferies revised stock ratings and price targets for several biotechnology companies, including Sarepta Therapeutics and Roivant Sciences, based on recent clinical trial data.

CNBC tracks the largest premarket stock fluctuations, highlighting significant gains and losses across healthcare, fitness, and biotech sectors.

Pharmaceutical companies Roivant Sciences and Priovant Therapeutics introduced the newly approved treatment Lisraya for rare diseases, setting a monthly price point of $35,000 upon its market debut.

Roivant Sciences has released its earnings preview for the first quarter of 2027, providing an outlook on its upcoming financial results.

Guggenheim has maintained its bullish stance on Roivant Sciences Ltd. (ROIV), signaling continued confidence in the company's prospects.

Roivant Sciences expects to receive a $950 million payment from Moderna in July and has outlined readouts for its mosliciguat and IMVT-1402 drug candidates in the second half of 2026.

Both Piper Sandler and Bernstein have expressed a bullish outlook on Roivant Sciences (ROIV) stock.

Bernstein has initiated coverage of Roivant Sciences Ltd. (ROIV) with an "Outperform" rating.